Platelet Function in Patients With an Acute Coronary Syndrome (ATLANTIS-ACS)
Association Between the Antiplatelet Drug Efficacy/Safety and Platelet Function in Patients Treated With Novel Platelet Inhibitors Due to an Acute Coronary Syndrome
The aims of the study are to:
- explore whether platelet reactivity in patients treated wih novel platelet inhibitors is associated with clinical outcome
- investigate whether a therapeutic window exist for novel platelet inhibitors
- investigate the incidence of adverse events under treatment with novel platelet inhibitors in the real life clinical scenario
- investigate the association between genetic polymorphisms, inflammation, platelet reactivity and clinical outcome
- investigate synergistic effects between aspirin and novel platelet inhibitors
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Jolanta M Siller-Matula, PD MD PhD
- Phone Number: 0043 1 404004614
- Email: jolanta.siller-matula@meduniwien.ac.at
Study Locations
-
-
-
Vienna, Austria
- Recruiting
- Medical Univerity of Vienna, Department of Cardiology
-
Principal Investigator:
- Jolanta M Siller-Matula, PD MD PhD
-
Principal Investigator:
- Georg Delle-Karth, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Signed informed consent
- Acute coronary syndrome at admission
- Planned treatment with novel platelet inhibitors
- Age >18
Exclusion Criteria:
* Participation in interventional trials
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Net clinical benefit.
Time Frame: 1 year
|
A composite of MACE and BARC=>2 bleedings.
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
MACE and Major bleeding
Time Frame: 1 year
|
MACE: the composite of stent thrombosis, cardiac death and myocardial infarction. Major Bleeding: BARC =>2, TIMI major, GUSTO moderate-severe-life threatening. |
1 year
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
single endpoints of acute coronary syndrome, myocardial infarction, cardiac death, all-cause death, urgent vessel revascularization (PCI or CABG), stroke.
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ATLANTIS-ACS
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.